Sino BiopharmaceuticalSBMFF -4.96%62 EBITDA Margin % is 7.94% as of Dec. 2025, which is 72% below its 10-year median of 28.10. GuruFocus rates SBMFF with a GF Score™ of 62/100 and a GF Value™ of $0.68 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 945 Biotechnology companies, Sino Biopharmaceutical ranks better than 84.97% on this metric.
Sino Biopharmaceutical (OTCPK:SBMFF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Sino Biopharmaceutical EBITDA Margin % Related Terms
Sino Biopharmaceutical EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Sino Biopharmaceutical's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SBMFF vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Sino Biopharmaceutical's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sino Biopharmaceutical EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Sino Biopharmaceutical's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sino Biopharmaceutical (SBMFF) has a EBITDA Margin % of 7.94% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sino Biopharmaceutical and its competitors. This is 72% below median its historical median of 28.10. Over the past decade, Sino Biopharmaceutical's EBITDA Margin % has ranged from 22.62 to 73.99. According to the industry distribution chart, Sino Biopharmaceutical ranks #142 out of 945 companies in the Biotechnology industry, placing it in the top 15%.
Is Sino Biopharmaceutical's EBITDA Margin % too high?
Sino Biopharmaceutical's current EBITDA Margin % of 7.94% is 72% below median its 10-year median of 28.10. Over the past 10 years, this metric has ranged from a low of 22.62 to a high of 73.99. Based on the distribution chart, Sino Biopharmaceutical ranks #142 out of 945 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Sino Biopharmaceutical has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sino Biopharmaceutical's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sino Biopharmaceutical ranks #142 out of 945 companies for EBITDA Margin %. This places Sino Biopharmaceutical in the top 15% of its industry — outperforming the majority of peers. Historically, Sino Biopharmaceutical's own EBITDA Margin % has ranged from 22.62 to 73.99 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sino Biopharmaceutical and its competitors. Sino Biopharmaceutical's current EBITDA Margin % is 7.94%, which is 72% below median its own 10-year median of 28.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sino Biopharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Sino Biopharmaceutical (SBMFF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.68, compared to a current price of $0.60 — trading 11.5% below its estimated fair value. The current EBITDA Margin % is 7.94%, which is 72% below median its 10-year median of 28.10. Sino Biopharmaceutical's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Sino Biopharmaceutical (SBMFF), the current EBITDA Margin % is 7.94% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sino Biopharmaceutical (SBMFF) Overvalued in 2026?
Based on GuruFocus' analysis, Sino Biopharmaceutical stock appears to be undervalued.
The current stock price of $0.60 is trading 11.5% below its estimated GF Value™ of $0.68.
GuruFocus considers Sino Biopharmaceutical to be Modestly Undervalued.
Key valuation signals for SBMFF:
EBITDA Margin %: 7.94% (72% below median its 10-year median of 28.10)
GF Value™: $0.68 vs. price of $0.60 (11.5% below fair value)
No single metric tells the full story. See the SBMFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sino Biopharmaceutical Ltd is an investment holding company. The company and its subsidiaries are principally engaged in the research and development, production and sale of a series of pharmaceutical products. Its business covering the entire industrial chain of R&D, production and commercialization of drugs, biological products and high-end generic drugs. The company's therapeutic areas include: oncology, liver disease, respiratory, and surgery/pain relief. The company's revenue was generated from the sale of pharmaceutical products in the Chinese mainland.
62GF Score
Get the complete analysis for SBMFF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SBMFF has been successfully added to your 
